Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1495905 | 0.99 | CREBBP (0.54) | CREBBPKDM4EGAAMEN1KMT2A | |
| SCHEMBL2616166 | 0.88 | SMN1; SMN2 (0.64) | KDM4EGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1495995 | 0.86 | KDM4E (0.50) | CREBBPKDM4EGAAMEN1KMT2A | |
| SCHEMBL1495991 | 0.80 | KDM4E (0.46) | KDM4EMEN1KMT2ATDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23247221 | 0.80 | KDM4E (0.69) | KDM4EGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL17991554 | 0.79 | MGLL (0.56) | KDM4EGAAALDH1A1TDP1 | |
| SCHEMBL5549183 | 0.77 | RXFP1 (0.44) | KDM4EMEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL6174157 | 0.77 | MCHR1 (0.62) | KDM4EGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL25314236 | 0.76 | TDP1 (0.57) | KDM4EGAAKMT2AALDH1A1TDP1 | |
| SCHEMBL12492829 | 0.76 | ALDH1A1 (0.55) | KDM4EGAAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2292621-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | CREBBP 4676/4885KDM4E 2842/4885GAA 4166/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | CREBBP 4676/4885KDM4E 2842/4885GAA 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.